Cargando…
Intrawound Vancomycin Powder for Spine Tumor Surgery
Study Design Retrospective evaluation of prospectively collected data. Objective To evaluate infection rates following intrawound vancomycin powder application during spine tumor surgery. Methods Patients ≥18 years old undergoing spine tumor surgery and receiving intrawound vancomycin powder at a si...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836938/ https://www.ncbi.nlm.nih.gov/pubmed/27099810 http://dx.doi.org/10.1055/s-0035-1558655 |
_version_ | 1782427789750697984 |
---|---|
author | Okafor, Richard Molinari, William Molinari, Robert Mesfin, Addisu |
author_facet | Okafor, Richard Molinari, William Molinari, Robert Mesfin, Addisu |
author_sort | Okafor, Richard |
collection | PubMed |
description | Study Design Retrospective evaluation of prospectively collected data. Objective To evaluate infection rates following intrawound vancomycin powder application during spine tumor surgery. Methods Patients ≥18 years old undergoing spine tumor surgery and receiving intrawound vancomycin powder at a single center between January 2008 and January 2015 were enrolled. Patient demographics (age, sex, body mass index [BMI]), tumor type (metastatic, primary) and location, surgical data (estimated blood loss [EBL], levels fused, type of decompression, length of surgery and hospitalization, discharge status from hospital), radiation therapy use, and infection rates (surgery to a minimum of 30 days postoperative) were evaluated. Results Forty patients (46 procedures) undergoing spine tumor surgery and intrawound vancomycin powder application were identified. Five were excluded because of death less than 30 days postoperatively, and 35 patients (41 procedures) were enrolled: 11 women and 24 men with an average age of 61.4 years (range 19 to 92) and average BMI of 27.3 (range 17.4 to 36.8). Three cases were primary spine tumors. Five were hematologic malignancies, and 27 were metastatic cancers. Twenty-one tumors were in the thoracic spine, 12 in the lumbar spine, and 8 in the cervical spine. Average EBL was 899 mL (range 25 to 3,500), average length of surgery was 241 minutes (range 78 to 495), and average hospital stay was 15.1 days (range 3 to 49). Two culture-proven infections (Staphylococcus aureus, Enterobacter cloacae) were noted in 41 procedures (4.9%). Ten patients (28.6%) had preoperative radiation only; 14 (40%) had postoperative radiation only, 5 (14.3%) had both preoperative and postoperative radiation, and 6 (17.1%) had no radiation. There were no associations between radiation treatment and postsurgical infections (p = 0.19). Conclusion In this first study evaluating intrawound vancomycin powder for spine tumor surgery, we report an infection rate of 4.9%. We found no correlations between radiation treatment and postsurgical infections. |
format | Online Article Text |
id | pubmed-4836938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-48369382016-05-01 Intrawound Vancomycin Powder for Spine Tumor Surgery Okafor, Richard Molinari, William Molinari, Robert Mesfin, Addisu Global Spine J Article Study Design Retrospective evaluation of prospectively collected data. Objective To evaluate infection rates following intrawound vancomycin powder application during spine tumor surgery. Methods Patients ≥18 years old undergoing spine tumor surgery and receiving intrawound vancomycin powder at a single center between January 2008 and January 2015 were enrolled. Patient demographics (age, sex, body mass index [BMI]), tumor type (metastatic, primary) and location, surgical data (estimated blood loss [EBL], levels fused, type of decompression, length of surgery and hospitalization, discharge status from hospital), radiation therapy use, and infection rates (surgery to a minimum of 30 days postoperative) were evaluated. Results Forty patients (46 procedures) undergoing spine tumor surgery and intrawound vancomycin powder application were identified. Five were excluded because of death less than 30 days postoperatively, and 35 patients (41 procedures) were enrolled: 11 women and 24 men with an average age of 61.4 years (range 19 to 92) and average BMI of 27.3 (range 17.4 to 36.8). Three cases were primary spine tumors. Five were hematologic malignancies, and 27 were metastatic cancers. Twenty-one tumors were in the thoracic spine, 12 in the lumbar spine, and 8 in the cervical spine. Average EBL was 899 mL (range 25 to 3,500), average length of surgery was 241 minutes (range 78 to 495), and average hospital stay was 15.1 days (range 3 to 49). Two culture-proven infections (Staphylococcus aureus, Enterobacter cloacae) were noted in 41 procedures (4.9%). Ten patients (28.6%) had preoperative radiation only; 14 (40%) had postoperative radiation only, 5 (14.3%) had both preoperative and postoperative radiation, and 6 (17.1%) had no radiation. There were no associations between radiation treatment and postsurgical infections (p = 0.19). Conclusion In this first study evaluating intrawound vancomycin powder for spine tumor surgery, we report an infection rate of 4.9%. We found no correlations between radiation treatment and postsurgical infections. Georg Thieme Verlag KG 2015-07-16 2016-05 /pmc/articles/PMC4836938/ /pubmed/27099810 http://dx.doi.org/10.1055/s-0035-1558655 Text en © Thieme Medical Publishers |
spellingShingle | Article Okafor, Richard Molinari, William Molinari, Robert Mesfin, Addisu Intrawound Vancomycin Powder for Spine Tumor Surgery |
title | Intrawound Vancomycin Powder for Spine Tumor Surgery |
title_full | Intrawound Vancomycin Powder for Spine Tumor Surgery |
title_fullStr | Intrawound Vancomycin Powder for Spine Tumor Surgery |
title_full_unstemmed | Intrawound Vancomycin Powder for Spine Tumor Surgery |
title_short | Intrawound Vancomycin Powder for Spine Tumor Surgery |
title_sort | intrawound vancomycin powder for spine tumor surgery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836938/ https://www.ncbi.nlm.nih.gov/pubmed/27099810 http://dx.doi.org/10.1055/s-0035-1558655 |
work_keys_str_mv | AT okaforrichard intrawoundvancomycinpowderforspinetumorsurgery AT molinariwilliam intrawoundvancomycinpowderforspinetumorsurgery AT molinarirobert intrawoundvancomycinpowderforspinetumorsurgery AT mesfinaddisu intrawoundvancomycinpowderforspinetumorsurgery |